What is the equity of Takara Bio this year?
Takara Bio has equity of 111.51 B JPY this year.
In 2024, Takara Bio's equity was 111.51 B JPY, a 16.3% increase from the 95.87 B JPY equity in the previous year.
Takara Bio's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Takara Bio's equity is essential for assessing its financial health, stability, and value to shareholders.
Evaluating Takara Bio's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Takara Bio's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Fluctuations in Takara Bio’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Takara Bio has equity of 111.51 B JPY this year.
The equity of Takara Bio has increased/decreased by 16.3% increased compared to the previous year.
A high equity is advantageous for investors of Takara Bio as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
A low equity can be a risk for investors of Takara Bio, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
An increase in equity of Takara Bio can strengthen the company's financial position and improve its ability to make investments in the future.
A reduction in equity of Takara Bio can affect the financial situation of the company and lead to a higher dependence on debt capital.
Some factors that can affect the equity of Takara Bio include profits, dividend payments, capital increases, and acquisitions.
The equity of Takara Bio is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
To change equity, Takara Bio can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
Over the past 12 months, Takara Bio paid a dividend of 17 JPY . This corresponds to a dividend yield of about 1.64 %. For the coming 12 months, Takara Bio is expected to pay a dividend of 19.79 JPY.
The current dividend yield of Takara Bio is 1.64 %.
Takara Bio pays a quarterly dividend. This is distributed in the months of April, April, April, April.
Takara Bio paid dividends every year for the past 16 years.
For the upcoming 12 months, dividends amounting to 19.79 JPY are expected. This corresponds to a dividend yield of 1.9 %.
Takara Bio is assigned to the 'Health' sector.
To receive the latest dividend of Takara Bio from 6/1/2024 amounting to 17 JPY, you needed to have the stock in your portfolio before the ex-date on 3/28/2024.
The last dividend was paid out on 6/1/2024.
In the year 2023, Takara Bio distributed 42 JPY as dividends.
The dividends of Takara Bio are distributed in JPY.
Our stock analysis for Takara Bio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Takara Bio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.